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Supplemental methods 
 
 
Patients 
 
Peripheral blood mononuclear cells (PBMCs) were harvested from patients and healthy adult donors 
after the provision of written consent and in accordance with the tenets of the Declaration of Helsinki. 
Patients 1 to 5 and Patient 7 were referred to Necker Children’s Hospital in Paris, and Patient 6 was 
from Miami Children’s Hospital (now Nicklaus Children's Hospital). Mononuclear cells were isolated 
by Ficoll-Hypaque density gradient centrifugation (d=1.077 g/ml; Lymphoprep, Axis-Shield, Oslo, 
Norway). 
 
Transduction of T-cells 
 
A self-inactivating (SIN) pCCLU3 LV plasmid containing either an elongation factor 1 alpha (EF1 
promoter and UNC13D fused with cyan fluorescent protein (CFP) or CFP alone was used to generate 
LVs, as previously described 21. Isolated PBMCs from seven unrelated patients with FHL3 
(Supplemental Table 1) were cultured in Pancerin medium (PAN Biotech) supplemented with 5% 
human AB serum, 100 IU/ml human pro-interleukin-2 (pro-IL2; Novartis) and 1% penicillin-
streptomycin. Cells from P1 to P4 were prestimulated with 2.5 µg/ml phytohaemagglutinin (Sigma-
Aldrich) and cells from P5-P7 were prestimulated Dynabeads human T-activator CD3/CD28 
(Invitrogen) for 48 hours in retronectin-coated plates (CH296, Takara). Concentrated vector was added 
at the indicated MOI and incubated with the cells overnight at 37°C. The cells were then washed and 
seeded into culture plates in the presence of pro-IL2 (100 IU/ml). Given that only low mumbers of 
PHA-activated PBMCs were available for P1 to P4, only the VSVG-LV transduction and the 
degranulation assay could be performed on these samples. All other comparisons of H/F-LV and 
VSVG-LV were performed on PBMCs from P5, P6 and P7. 
 
 
Analysis of Munc 13-4 expression 
mRNA expression: RNA was extracted using RNeasy Mini Kit (Qiagen). Reverse 
transcription was performed using a High Capacity cDNA RT kit (Applied Biosystems). In 
qPCR experiments, Munc13-4 and GAPDH (for normalization) were amplified using 
Hs00397680-m1 and Hs00266705-g1 kits (Life Technologies), respectively.  
Protein expression: cells were lysed using RIPA lysis buffer, and cell extracts were separated on 
a 4-12% bis-tris acrylamide gel (Invitrogen) and transferred onto a PVDF membrane. The membrane 
was blocked in PBS supplemented with 0.05% Tween 20 and 5% dried milk powder, and then 
incubated with the primary antibodies: rabbit anti-Munc13-4 (NBP2-19442; Novus Biologicals) and 
mouse anti-GAPDH (MAB374; Millipore). After staining with horseradish-peroxidase-conjugated 
secondary antibodies (ThermoFisher Scientific), the immunoblots were developed using Fusion Fx-7 
Spectra (Vilber Lourmat). 
 
The degranulation assay 
Six days after transduction, activated T-cells were incubated with culture medium alone or culture 
medium supplemented with 3, 10 or 30 µg/ml of the anti-human CD3 antibody (clone OKT3) in the 
presence of PE-conjugated anti-CD107a/b (clone H4B4). After a 4-hour incubation at 37°C, cells were 
stained with the fluorochrome-conjugated antibodies CD3-APC (clone BW264/56) and CD8-FITC 
(clone BW135/80), and the cell viability dye 7-aminoactinomycin D (7-AAD). 
 
Generation of an EBV-transformed B- lymphoblastoid cell line (B-LCL) and EBV-specific 
cytotoxic T-cells 
Five million PBMCs from P5 (an EBV-seropositive patient) were incubated with 200 µl of 
concentrated supernatant from the B95-8 EBV-producer cell line for 1 hr at 37°C. Cells were then 
suspended in complete medium, consisting of RPMI-1640 (Gibco, BRL) supplemented with 10% 
foetal bovine serum (FBS, Hyclone, Logan, UT), 2 mmol/L L-glutamine (Gibco, BRL), and 1 µg/ml 
of cyclosporine A (CSA, Sandoz). Cells were fed weekly and expanded for long-term culture. 
EBV-specific T-cells (EBV-T-cells) were generated as previously described 22. Briefly, PBMCs were 
restimulated with irradiated LCLs at 4000 rads (40:1 ratio). After ten days, cells were restimulated and 
expanded by weekly restimulation with irradiated LCL at a T-cell:B-LCL ratio of 4:1 in the presence 
of human pro-IL 2 (40 U/ml). EBV-T-cells were transduced with H/F-LV expressing Munc13-4/CFP 
or H/F-LV expressing CFP alone (at an MOI of 5) three days after the third restimulation. Transgene 
expression was assessed one week after transduction (a FACS analysis of CFP expression).  
 
Establishment of the NSG xenograft mouse model 
The xenograft NOD/SCID/IL2rnull (NSG) mouse model and bioluminescence imaging were 
implemented as described elsewhere 14. Briefly, NSG mice were inoculated with 5 × 106 B-LCLs 
engineered to express firefly luciferase subcutaneously on the nape of the neck on day 0. Seven days 
later, mice received 5 × 106 transduced autologous EBV-T-cells intravenously (7 days after 
transduction of EBV-T-cells). Mice also received a daily intraperitoneal injection of human pro-IL2 
(2500 U) for 8 days, starting on the day before the injection of EBV-T-cells. Tumour growth was 
evaluated using the IVIS imaging system monitoring the expression of luciferase by the tumour mass 
(Xenogen; Caliper life Sciences, Hopkinton, MA). For flow cytometry analysis, tumour samples were 
first minced through a 70-μm pore size nylon mesh. Single cells were collected, stained with an anti-
human CD3 antibody (BD Bioscience) and measured with an LSR II FACS system (BD Biosciences). 
Samples were analysed with Flow Jo software ((version 10.0.7; Treestar, Ashland, OR) by comparing 
human T cells with BFP-expressing lymphoma B cells. Dead cells (stained with 7-AAD) were 
excluded. 
  
 
Flow cytometry analysis  
Cells were processed on a MACSQuant flow cytometer (Miltenyi Biotec), and the results were 
analyzed with FlowJo software (Treestar). Monoclonal antibodies against CD3-APC (BW264/56), 
CD8-Vioblue (BW135/80), CD45RA-APCVIO770 (T6D11), CD62L-PE (DREG-56), CD95-PECY7 
(DX2) and 7-AAD were used for cell surface staining. All antibodies used in flow cytometry analysis 
were purchased from BD Biosciences and Miltenyi Biotec. 
 
  
Supplemental figure legends 
 
 
 
Supplemental Figure 1. Lentiviral constructs and T-cell infiltration into a B-LCL 
lymphoma tumour. (A) A schematic representation of the lentiviral constructs used in this 
study, containing CFP alone or UNC13D cDNA fused with CFP (B) Upper panel: 
immunohistochemistry of human T-cell infiltration (CD3 staining) on a tumour section from 
xenograft NSG mice 30 days after EBV-T-cell infusion. The image evidences high levels of 
human CD3+ T-cell infiltration into the B-cell lymphoma in mice treated with Munc13-
4/CFP-transduced EBV-T-cells (relative to mice receiving control CFP EBV-T-cells). A 
representative image is shown. Scale bar: 100 µm; lower panel: flow cytometry analysis of 
tumour digests from NSG mice. Tumor cells expressing luciferase were also stained with an 
anti-human CD3 monoclonal antibody. 
 
 
Supplemental Figure 2. TSCM targeting and persistence during the ex vivo transduction 
protocol. (A) Plots of the CD8+ T-cell population from two representative FHL3 patients (of the three 
patient samples tested: P5 to P7), showing the proportions (in %) of different T-cell subpopulations; 
TN: naïve precursors, TCM: T central memory, TEM: T effector memory, TEMRA: T effector memory 
45RA+. (B) The mean number of Munc13-4/CFP+ cells as a percentage of TSCM (CD45RA+, CD62L+, 
and CD95+) cells six days after the transduction of activated T-cells. n=3; *p<0.05 in an unpaired t-
test (C) PBMCs from FHL3 patients were stimulated in vitro with anti-human T-cell activator 
CD3/CD28 Dynabeads + pro-IL2 (100 U/ml) for 48 hours and then cultured for 6 days with pro-IL2 
(100 U/ml). The graph presents the proportions of CD8+ T-cell subpopulations prior to stimulation and 
then 48 hours and 8 days after stimulation. d8 (H/F): cells transduced with H/F-LV (MOI: 5) on day 8 
of culture (6 days post-transduction). d8 (VSVG): cells transduced with VSVG-LV (MOI: 100) on day 
8 of culture (6 days post-transduction). 
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Supplementary	Table	1.	Data	on	the	patients’	mutations	and	initial	laboratory	results	
Patient	 Mutation	 Munc13-4	expression	
(Western	blot)		
CD107	surface	expression	
by	CTLs*	
1	 c.2093(-1)G>A	(splice	site)	
c.2346_49delGGAG	(p.Arg782fsX12)		
Absent	 Lower	than	in	controls	
2	 c.1822_1833del	(del	V608_A611)	 Absent	 Lower	than	in	controls	
3	 c.2296C>T	(p.Q766X)	
c.2477_80del	(p.L826fsX20)	
Absent	 Lower	than	in	controls	
4	 c.1389(+1)G>A	(splice	site)	
c.753(+1)G>T	(splice	site)	
Absent	 Lower	than	in	controls	
5	 c.1822_1833del	(del	V608_A611)	 Absent	 Lower	than	in	controls	
6	 c.154(-1)G>C	(splice	site)	
253kb	inversion	
Absent	 Lower	than	in	controls	
7	 c.916C>T	(p.Q306X)	
c.1193C>T	(p.S398L)	
Very	low	
	
Lower	than	in	controls	
*	CTL:	cytotoxic	T	lymphocyte	activity,	determined	as	the	level	of	CD107	surface	expression	by	fluorescence-activated	cell	
sorting	after	4	hours	of	stimulation	with	anti-CD3	antibody. 
Supplemental Figure 1. 
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